Novo Nordisk · 8 hours ago
Internship - Computational Biology
Lexington, MA, US
Internship
Onsite
InternNovo Nordisk is a global pharmaceutical company focused on life science innovation. The internship program allows students to gain hands-on experience while contributing to projects in computational biology, specifically in protein-RNA interactions and data processing for sequencing datasets.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Help implement or extend a data processing pipeline for chimeric eCLIP-seq data using publicly available tools and workflows, workflow management platform (Seqera/Nextflow) and containerization (Docker/Singularity)
Run reproducible and scalable workflows on Seqera to analyze multiple chimeric eCLIP-seq datasets, single-cell transcriptomics datasets, and collaborate with wet-lab scientists and bioinformaticians
Gain insights into cell type delivery of and the interactions between therapeutic siRNAs and the AGO2 protein and profile the targetome of individual therapeutic siRNAs
Qualification
Required
Must be a current student enrolled at an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
An in progress undergraduate or graduate degree in Computational Biology, Bioinformatics, Computer Science, Statistics or a related discipline preferred
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
2026-02-09
Company data provided by crunchbase